Summary
Nocturne GmbH, founded in 2018, is a spin-off from the Charité – Universitätsmedizin Berlin, Germany developing software solutions to efficiently process retina image data for neurological applications at scale across devices using advanced AI-based analysis. The innovative and unique technology developed tackles one the current major challenges in healthcare, the rapidly increasing burden of brain diseases. With the increase of life expectancy and aging population neurological disorders are the leading cause of disability and the second leading cause of death worldwide. The greatest unmet needs are better, faster and more cost-effective diagnostic and monitoring tools that could be widely available and have the potential to detect these diseases at the earliest stage in order to delay disability and provide each patient with a personalized treatment.
To address this the team of Nocturne identified two major opportunities, the use of the retina as a window to the brain, and an already established on the market hardware imaging technology, cost-effective, widely available with no burden for the patient that can capture retinal images in less than 5 minutes.
With its product, Nocturne addresses customers in pharmaceutical research, academia, and clinical care. In Germany alone, more than 1 million patients suffer from relevant diseases like Multiple Sclerosis, Parkinson’s disease, and others. We estimate the annual market volume in Germany alone at 350 million€, in Europe at 2 billion€.
At market entry, Nocturne product is a CE-certified local installable web service, which accepts data from standard retinal imaging devices.
The data are then analyzed with Nocturne’s technology, and a report is generated for the physician. The pricing is based on a pay-per-analysis, a model commonly used, for example, in radiology.
Our focus is by removing the technical barriers and by providing unique insights into the diseases to enable better disease management and patient care.
To address this the team of Nocturne identified two major opportunities, the use of the retina as a window to the brain, and an already established on the market hardware imaging technology, cost-effective, widely available with no burden for the patient that can capture retinal images in less than 5 minutes.
With its product, Nocturne addresses customers in pharmaceutical research, academia, and clinical care. In Germany alone, more than 1 million patients suffer from relevant diseases like Multiple Sclerosis, Parkinson’s disease, and others. We estimate the annual market volume in Germany alone at 350 million€, in Europe at 2 billion€.
At market entry, Nocturne product is a CE-certified local installable web service, which accepts data from standard retinal imaging devices.
The data are then analyzed with Nocturne’s technology, and a report is generated for the physician. The pricing is based on a pay-per-analysis, a model commonly used, for example, in radiology.
Our focus is by removing the technical barriers and by providing unique insights into the diseases to enable better disease management and patient care.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101072301 |
| Start date: | 01-06-2022 |
| End date: | 30-11-2022 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
Nocturne GmbH, founded in 2018, is a spin-off from the Charité – Universitätsmedizin Berlin, Germany developing software solutions to efficiently process retina image data for neurological applications at scale across devices using advanced AI-based analysis. The innovative and unique technology developed tackles one the current major challenges in healthcare, the rapidly increasing burden of brain diseases. With the increase of life expectancy and aging population neurological disorders are the leading cause of disability and the second leading cause of death worldwide. The greatest unmet needs are better, faster and more cost-effective diagnostic and monitoring tools that could be widely available and have the potential to detect these diseases at the earliest stage in order to delay disability and provide each patient with a personalized treatment.To address this the team of Nocturne identified two major opportunities, the use of the retina as a window to the brain, and an already established on the market hardware imaging technology, cost-effective, widely available with no burden for the patient that can capture retinal images in less than 5 minutes.
With its product, Nocturne addresses customers in pharmaceutical research, academia, and clinical care. In Germany alone, more than 1 million patients suffer from relevant diseases like Multiple Sclerosis, Parkinson’s disease, and others. We estimate the annual market volume in Germany alone at 350 million€, in Europe at 2 billion€.
At market entry, Nocturne product is a CE-certified local installable web service, which accepts data from standard retinal imaging devices.
The data are then analyzed with Nocturne’s technology, and a report is generated for the physician. The pricing is based on a pay-per-analysis, a model commonly used, for example, in radiology.
Our focus is by removing the technical barriers and by providing unique insights into the diseases to enable better disease management and patient care.
Status
SIGNEDCall topic
HORIZON-EIE-2021-SCALEUP-01-03Update Date
09-02-2023
Images
No images available.
Geographical location(s)
